What other conditions could weight-loss drugs treat?

According to data provider Airfinity, there are 66 ongoing, late-stage trials of GLP-1 drugs for obesity, diabetes and a range of other conditions linked to excess weight. Foto: Scott Olson/AFP/Ritzau Scanpix

Article republished from Financial Times

Ian Johnston and Michael Peel in London, Financial Times

12. dec. 2024 KL. 10.48

Gem til senere

Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart disease and Alzheimer’s

Børsens nyhedschef Louise Vogdrup-Schmidt anbefaler denne artikel fra Financial Times fordi:

Vi ved det godt – vægttabsmedicin er på en kæmpe bølge
Men vægttabsmidlerne har meget større potentiale end alene at afhjælpe vægttab, viser en grundig kortlægning fra Financial Times

One of Dr Mo Sarhan’s patients was experiencing intense cravings for opioids and alcohol when the Florida-based doctor offered him a striking solution: the Eli Lilly weight-loss drug Mounjaro.

NÆVNTE EMNER: Financial Times